Research Article

Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma

Table 2

Association of clinicopathological parameters with estrogen and progesterone receptor expression.

Clinicopathological parametersValuesp-Value
ER/PR expression
PositiveNegative

Age (years), Mean ± SD53.17 ± 13.1651.70 ± 11.730.504
Age group
 ≤35 years, n (%)2 (4.3)14 (14.9)0.181
 36–50 years, n (%)18 (39.1)34 (36.2)
 >50 years, n (%)26 (56.5)46 (48.9)
 Follow-up duration (months), Mean ± SD4.52 ± 1.883.95 ± 1.860.096
Tumor laterality
 Right breast, n (%)20 (43.5)58 (61.7)0.041
 Left breast, n (%)26 (56.5)36 (38.3)
 Tumor size (cm), n = 924.20 ± 1.886.62 ± 3.430.003
Tumor (T) stage, n = 92
 T1, n (%)4 (16.7)8 (11.8)<0.001
 T2, n (%)16 (66.7)18 (26.5)
 T3, n (%)4 (16.7)42 (61.8)
Tumor grade
 Grade 2, n (%)20 (43.5)14 (14.9)<0.001
 Grade 3, n (%)26 (56.5)80 (85.1)
Squamous differentiation
 Present, n (%)30 (65.2)66 (70.2)0.550
 Absent, n (%)16 (34.8)28 (29.8)
Chondroid differentiation
 Present, n (%)4 (8.7)4 (4.3)0.439
 Absent, n (%)42 (91.3)90 (95.7)
Spindle cell differentiation
 Present, n (%)4 (8.7)12 (12.8)0.477
 Absent, n (%)42 (91.3)82 (87.2)
Nodal (N) stage, n = 92, n (%)
 N0, n (%)14 (58.3)38 (55.9)0.107
 N1, n (%)4 (16.7)14 (20.8)
 N2, n (%)5 (20.8)4 (5.9)
 N3, n (%)1 (4.2)12 (17.6)
Recurrence, n (%)
 Yes, n (%)20 (43.5)24 (25.5)0.032
 No, n (%)26 (56.5)70 (74.5)
Survival status, n (%)
 Alive, n (%)34 (73.9)66 (70.2)0.649
 Expired, n (%)12 (26.1)28 (29.8)

Independent t-test was applied, Chi-square/Fisher’s exact test was applied, p-value significant as <0.05. ER: estrogen receptor; PR: progesterone receptor; SD: standard deviation; T: tumor; N: nodal.